Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity

Iovance Biotherapeutics’ (NASDAQ: IOVA ) stock collapsed on May 9 after its first‑quarter report revealed a significant earnings miss. The company lost $0.36 per share in Q1 (versus a consensus $0.24 loss), and revenue was $49.3 million, which was well below the $81.53 millionAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my o ...